Jazz Pharmaceuticals plc Lease, Cost
Jazz Pharmaceuticals plc (JAZZ) reported Lease, Cost of $31.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-24
- Jazz Pharmaceuticals plc lease, cost for the quarter ending 2021-12-31 was $6.30M, a 9.06% decline year-over-year.
- Jazz Pharmaceuticals plc lease, cost for the quarter ending 2021-09-30 was $8.65M, a 34.25% increase year-over-year.
- Jazz Pharmaceuticals plc lease, cost for the quarter ending 2021-06-30 was $8.16M, a 30.93% increase year-over-year.
- Jazz Pharmaceuticals plc lease, cost for the quarter ending 2021-03-31 was $6.92M, a 15.29% increase year-over-year.
- Jazz Pharmaceuticals plc lease, cost for fiscal 2025 was $31.46M, a 2.08% increase from fiscal 2024.
- Jazz Pharmaceuticals plc lease, cost for fiscal 2024 was $30.82M, a 15.87% increase from fiscal 2023.
- Jazz Pharmaceuticals plc lease, cost for fiscal 2023 was $26.60M, a 3.65% increase from fiscal 2022.
- Jazz Pharmaceuticals plc lease, cost for fiscal 2022 was $25.66M, a 14.56% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $31.46M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $30.82M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $26.60M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $25.66M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $14.96M derived: sum of 2 quarters · filed 2024-02-28 | $23.12M derived: sum of 3 quarters · filed 2024-02-28 | $30.04M 10-K · filed 2024-02-28 |
| 2021-09-30 | $8.65M 10-Q · filed 2021-11-09 | $16.81M derived: sum of 2 quarters · filed 2021-11-09 | $23.73M 10-Q · filed 2021-11-09 | $30.67M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $8.16M 10-Q · filed 2021-08-03 | $15.08M 10-Q · filed 2021-08-03 | $22.02M derived: sum of 3 quarters · filed 2023-03-01 | $28.46M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.92M 10-Q · filed 2021-05-04 | $13.85M derived: sum of 2 quarters · filed 2023-03-01 | $20.30M derived: sum of 3 quarters · filed 2023-03-01 | $26.53M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $13.38M derived: sum of 2 quarters · filed 2023-03-01 | $19.61M derived: sum of 3 quarters · filed 2023-03-01 | $25.61M 10-K · filed 2023-03-01 |
| 2020-09-30 | $6.44M 10-Q · filed 2021-11-09 | $12.68M derived: sum of 2 quarters · filed 2021-11-09 | $18.68M 10-Q · filed 2021-11-09 | $24.79M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $6.23M 10-Q · filed 2021-08-03 | $12.24M 10-Q · filed 2021-08-03 | $18.35M derived: sum of 3 quarters · filed 2022-03-01 | $24.33M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $6.00M 10-Q · filed 2021-05-04 | $12.11M derived: sum of 2 quarters · filed 2022-03-01 | $18.10M derived: sum of 3 quarters · filed 2022-03-01 | $24.61M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $12.09M derived: sum of 2 quarters · filed 2022-03-01 | $18.61M derived: sum of 3 quarters · filed 2022-03-01 | $24.92M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.98M 10-Q · filed 2020-11-02 | $12.50M derived: sum of 2 quarters · filed 2020-11-02 | $18.81M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $6.52M 10-Q · filed 2020-08-04 | $12.83M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $6.31M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |